LVTX

Analyst Sentiment

Wall St. Consensus
Hold
6 analysts·Limited coverage
58
Score
2 Buy (33%)4 Hold (67%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
233%
Hold
467%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$1.50
-13.8%
Consensus
$3.75
+115.5%
Bull
$6.00
+244.8%
12-Month Target Range6 analysts
$1.50$3.75$6.00
Current $1.74Consensus
Current Price
$1.74
Upside to Consensus
$2.01

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev-82.94%
EPS
FY2028
Rev+563.05%
EPS
FY2029
Rev+135.82%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029E
Revenue Avg$23M$4M$26M$61M
Low$23M$4M$26M$61M
High$23M$4M$26M$61M
EBITDA Avg$-13M$-10M$-5M$-4M
Low$-13M$-10M$-5M$-4M
High$-13M$-10M$-5M$-4M
EBIT Avg$-14M$-11M$-6M$-6M
Low$-14M$-11M$-6M$-6M
High$-14M$-11M$-6M$-6M
Net Income Avg$-14M$-11M$-7M$-7M
Low$-14M$-11M$-7M$-7M
High$-14M$-11M$-7M$-7M
EPS Avg$-0.54$-0.41$-0.25$-0.25
Low$-0.54$-0.41$-0.25$-0.25
High$-0.54$-0.41$-0.25$-0.25
Analysts (Rev / EPS)1 / 11 / 11 / 11 / 1
Quarterly
MetricQ3 2026Q4 2026
Revenue Avg
Low
High
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-5M$-2M
Low$-5M$-2M
High$-5M$-2M
EPS Avg$-0.19$-0.06
Low$-0.19$-0.06
High$-0.19$-0.06
Analysts (Rev / EPS) / 1 / 1

Earnings Surprises

Recent Analyst Actions

Aug 5, 2025Jefferies
Lava Therapeutics downgraded to Hold from Buy at Jefferies
Target:$1.50
-0.7%from $1.51
Jun 28, 2024H.C. Wainwright
H.C. Wainwright Reiterates Buy Rating on Lava Therapeutics NV (LVTX)
Target:$6.00
+219.1%from $1.88
Mar 20, 2024Jefferies
Jefferies Reiterates Buy Rating on Lava Therapeutics NV (LVTX) Following Earnings, 'LAVA 1266 tracking to 2Q24 IND submission'
Target:$6.00
+95.4%from $3.07
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.